002868.SHE Lifecome Biochemistry Co Ltd
- Market cap
- CNY 2.83B
- P/E
- -
- P/B
- 39.49x
- ROE
- 13.5%
- Dividend yield
- 1.50%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002868.SHE undervalued?
Graham numberThe Graham number of Lifecome Biochemistry Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Lifecome Biochemistry Co Ltd fundamental analysis
No fundamental analysis for Lifecome Biochemistry Co Ltd yet.
Lifecome Biochemistry Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Lifecome Biochemistry Co Ltd
Lifecome Biochemistry Co.,Ltd. engages in research, development, production, and sales of veterinary drugs in China. It offers probiotics and green microbial functional additives; biopesticides, biofertilizers, and pesticide formulations; and food additives. The company was founded in 2003 and is based in Pucheng, China.
Full company profileLifecome Biochemistry Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Lifecome Biochemistry Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 401M | 375M | 344M | 304M | 308M | 363M | 330M | 507M | 649M | 517M | 462M |
| Gross Profit | 157M | 150M | 116M | 98.7M | 91.7M | 51.8M | -51.5M | -105M | -107M | 34.6M | 93.1M |
| Operating Income | 104M | 101M | 87.2M | 67.0M | 48.0M | -33.1M | -134M | -236M | -428M | -128M | 47.7M |
| EBITDA | 140M | 129M | 117M | 95.8M | 79.9M | 4.67M | -53.6M | -134M | -269M | 13.1M | 26.9M |
| Net Income | 92.4M | 85.9M | 74.7M | 57.0M | 43.2M | -26.0M | -122M | -222M | -445M | -139M | 9.56M |
| EPS | 0.79 | 0.60 | 0.48 | 0.37 | 0.28 | -0.17 | -0.79 | -1.44 | -2.86 | -0.90 | 0.06 |
| Balance Sheet | |||||||||||
| Total Assets | 371M | 756M | 802M | 1.01B | 973M | 1.26B | 1.24B | 1.97B | 1.49B | 749M | 721M |
| Total Liabilities | 99.3M | 60.6M | 62.0M | 232M | 203M | 536M | 641M | 1.55B | 1.52B | 684M | 649M |
| Shareholders' Equity | 271M | 696M | 740M | 774M | 765M | 718M | 596M | 411M | -26.3M | 63.2M | 71.0M |
| Cash & Short-term Investments | 15.6M | 71.7M | 68.7M | 287M | 194M | 97.5M | 23.8M | 84.4M | 24.8M | 55.6M | 42.8M |
| Total Debt | 33.2M | 1.22M | - | 122M | 82.1M | 308M | 357M | 963M | 330M | 186M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 135M | 96.1M | 83.7M | 74.1M | 90.7M | 35.2M | -8.83M | -187M | 141M | -25.1M | - |
| Capital Expenditure | 14.8M | 18.6M | 48.9M | 126M | 254M | 357M | 137M | 465M | 125M | 130M | 39.5M |
| Free Cash Flow | 121M | 77.5M | 34.8M | -51.5M | -163M | -322M | -146M | -651M | 16.4M | -155M | 27.7M |
| Ratios | |||||||||||
| ROE | 34.0% | 12.4% | 10.1% | 7.4% | 5.6% | -3.6% | -20.5% | -53.9% | - | -220.4% | 13.5% |
| ROA | 24.9% | 11.4% | 9.3% | 5.6% | 4.4% | -2.1% | -9.8% | -11.3% | -29.8% | -18.6% | 1.3% |
| Net Profit Margin | 23.0% | 22.9% | 21.7% | 18.8% | 14.0% | -7.2% | -37.0% | -43.8% | -68.5% | -27.0% | 2.1% |
| Debt to Equity | 0.12x | 0.00x | - | 0.16x | 0.11x | 0.43x | 0.60x | 2.34x | - | 2.95x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Lifecome Biochemistry Co Ltd dividends
- Dividend yield
- 1.50%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- May 21, 2021
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 42.5M | 0.27 | - |
| 2024 | CNY 48.8M | 0.31 | - |
| 2023 | CNY 24.2M | 0.16 | - |
| 2022 | CNY 13.0M | 0.08 | - |
| 2021 | CNY 21.5M | 0.14 | - |
| 2020 | CNY 20.1M | 0.13 | 46.4% |
| 2019 | CNY 30.0M | 0.19 | 52.7% |
| 2018 | CNY 30.0M | 0.19 | 40.2% |
| 2017 | CNY 30.4M | 0.21 | 35.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.3:1 on May 28, 2020.
Who owns Lifecome Biochemistry Co Ltd
- Insiders 59.33%
- Institutions 5.03%
- Public & others 35.64%
- Shares outstanding 155M
- Free float 46.4M
Lifecome Biochemistry Co Ltd company profile
- Company name
- Lifecome Biochemistry Co Ltd
- Ticker
- 002868.SHE
- ISIN
- CNE100002QH2
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 549
- Fiscal year end
- December
- Address
- No. 6, Yuanyuan Road, Pucheng, China, 353400
- Phone
- 86 59 9282 7451
- Website
- pclifecome.com
About Lifecome Biochemistry Co Ltd
Lifecome Biochemistry Co.,Ltd. engages in research, development, production, and sales of veterinary drugs in China. It offers probiotics and green microbial functional additives; biopesticides, biofertilizers, and pesticide formulations; and food additives. The company was founded in 2003 and is based in Pucheng, China.
Lifecome Biochemistry Co Ltd management
4- Ms. Jing YangActing GM & Director · born 1986
- Mr. Zhongshou BaoFinancial Director · born 1970
- Xiaohong WangAccounting Supervisor
- Mr. Guo Feng GaoSecretary of Board · born 1984